A Phase I/II Randomized, Open-Labeled Study to Evaluate Pharmacokinetic and Pharmacodynamic Effects and Safety of ALZT-OP1 in Subjects With Alzheimer's Disease and Normal Healthy Volunteers
Latest Information Update: 04 Mar 2022
At a glance
- Drugs Ibuprofen (Primary) ; Ibuprofen+sodium cromoglicate (Primary) ; Sodium cromoglicate (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacokinetics
- Sponsors AZTherapies
- 01 Nov 2021 Status changed from recruiting to completed.
- 01 Oct 2020 New trial record